<DOC>
	<DOCNO>NCT02804945</DOCNO>
	<brief_summary>The goal clinical research study learn safety give mesenchymal stem cell ( MSCs ) patient ARDS . Researchers also want learn cell help control ARDS give drug routinely use treat ARDS . In study , participant receive standard care treatment ARDs , participant receive standard care treatment MSCs .</brief_summary>
	<brief_title>Mesenchymal Stem Cells ( MSCs ) Treatment Acute Respiratory Distress Syndrome ( ARD ) Stem Cell Transplant Patients</brief_title>
	<detailed_description>The MSCs : MSCs type stem cell remove bone marrow grow many different cell type use treat cancer disease . The MSCs use study collect healthy donor store grown laboratory MD Anderson . The product participant receive healthy donor relate participant . Study Groups : If participant find eligible take part study , participant randomly assign ( flip coin ) 1 2 study group participant equal chance either group . This do one know one study group well , , bad group . - If participant Group 1 , participant receive MSCs standard care drug ARDS . - If participant Group 2 , participant receive standard care drug ARDS . MSC Administration : If participant Group 1 , participant receive MSCs vein 1-2 hour 1 time Day 1 . Both group also receive standard care drug treatment ARDS . The study doctor tell participant drug participant take , risk , participant take . Study Visits : On Days 1 3 : - Blood ( 2 tablespoon ) draw routine test , check participant 's heart , kidney , liver function , biomarker test . - Blood ( ½ teaspoon ) drawn check oxygen level participant 's blood . On Days 14 28 : °Blood ( 2 tablespoon ) draw routine test , check participant 's heart , kidney , liver function , biomarker test . On Days 30 60 : °Participant check possible reaction participant 's treatment , include graft-versus-host disease ( GVHD - reaction donor 's immune cell participant 's body ) . This checked physical exam , doctor review participant 's side effect , blood standard care blood draw . At Months 6 12 : - Participant physical exam . - Participant check possible reaction participant 's treatment , include graft-versus-host disease ( GVHD - reaction donor 's immune cell participant 's body ) . This checked physical exam , doctor review participant 's side effect , blood standard care blood draw . - Participant lung function test . Length Study : Participation study end Month 12 study visit . Participant take study early participant able receive MSC infusion ( ) , intolerable side effect occur , doctor think participant 's best interest , participant unable follow study direction . This investigational study . MSC infusion treatment ARDS investigational . Up 50 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<criteria>1 . ARDS characterize hypoxemia bilateral radiographic opacity fully explain cardiac failure fluid overload judge treat physician use available data . Moderate ARDS include stem cell transplant patient previous presentation P/F ratio &lt; /= 200 S/F ratio &lt; /= 214 . The duration hypoxemia criterion radiograph criterion must &lt; /= 96 hour time enrollment . 2 . Stem Cell transplant patient age &gt; /=18 year . 3 . Treated appropriate maximal medical therapy pulmonary toxicity . 4 . Patient must achieve 2hour stable baseline period order eligible receive product infusion , define transcutaneous oxygen saturation target range 8895 % without increase ventilator setting stable vasopressor use patient require vasopressor blood pressure support . 5 . Negative pregnancy test woman childbearing potential define postmenopausal 12 month previous surgical sterilization . 6 . Patient legally appropriate proxy must able understand study instruction sign consent . 1 . NYHA class IV heart failure . 2 . Unstable ventricular tachycardia fibrillation . 3 . Moribund patient expect survive 48 hour . 4 . Patients ARDS result trauma . 5 . Patients WHO Class III IV pulmonary hypertension . 6 . Patients document deep venous thrombosis pulmonary embolism within past 3 month . 7 . Patients severe chronic liver disease ( ChildsPugh score &gt; 10 ) . 8 . Patients previous solid organ transplant . 9 . Patients allergic betalactam antibiotic , use manufacturing hMSCs . 10 . Pregnant and/or lactate woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Blood And Marrow Transplantation</keyword>
	<keyword>Adult Respiratory Distress Syndrome</keyword>
	<keyword>ARDS</keyword>
	<keyword>Allogeneic human mesenchymal stem cell</keyword>
	<keyword>hMSCs</keyword>
	<keyword>Placebo</keyword>
	<keyword>Plasma-Lyte A solution</keyword>
	<keyword>Standard Care</keyword>
	<keyword>Recent onset pulmonary toxicity</keyword>
</DOC>